COBRA1 Antibody [K14G15] | Primary Antibodies

Application: Reactivity: Human, Mouse, Rat, Monkey

Usage Information

Dilution
WB1:1000 IP1:50 CHIP1:50

Application
WB, IP, ChIP

Reactivity
Human, Mouse, Rat, Monkey

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
65 kDa

Positive Control	MCF7 cells; NIH/3T3 cells; KNRK cells; COS-7 cells
Negative Control

Datasheet & SDS

Biological Description

Specificity
COBRA1 (D6K9A) Rabbit mAb detects endogenous levels of total COBRA1 protein.

Clone
K14G15

Synonym(s)
Negative elongation factor B; NELF-B; Cofactor of BRCA1; NELFB; COBRA1; KIAA1182

Background
COBRA1 (NELF-B), a core subunit of the Negative Elongation Factor (NELF) complex alongside WHSC2 (NELF-A), TH1L (NELF-C/D), and NELF-E, is a critical regulator of RNA polymerase II (RNAPII) transcription elongation, promoting promoter-proximal pausing in concert with DSIF and awaiting P-TEFb-mediated release through phosphorylation of both NELF and the RNAPII CTD for productive elongation. COBRA1 is predicted to adopt a HEAT repeat fold, mediating essential intersubunit interactions that anchor NELF-A and RNA-binding NELF-E, thereby stabilizing the NELF complex and facilitating its association with paused RNAPII approximately 20–60 bp downstream of promoters. COBRA1’s principal functions include maintaining RNAPII pausing to allow rapid, signal-dependent gene induction, particularly at developmental and stress-responsive genes, modulating nuclear receptor activity (estrogen, androgen, glucocorticoid receptors) to control target gene expression and alternative splicing, and negatively regulating AP-1 at promoters such as TFF1; notably, it was initially identified through its BRCT-domain interaction with the BRCA1 tumor suppressor. COBRA1 fine-tunes transcriptional output for energy metabolism genes in cardiomyocytes, governs stem cell differentiation, and modulates hormone-driven proliferation. Clinically, reduced COBRA1 expression correlates with poor prognosis in metastatic or recurrent breast cancer, whereas its overexpression promotes androgen receptor signaling and tumor growth/migration in prostate and hepatocellular cancers.

Background

COBRA1 (NELF-B), a core subunit of the Negative Elongation Factor (NELF) complex alongside WHSC2 (NELF-A), TH1L (NELF-C/D), and NELF-E, is a critical regulator of RNA polymerase II (RNAPII) transcription elongation, promoting promoter-proximal pausing in concert with DSIF and awaiting P-TEFb-mediated release through phosphorylation of both NELF and the RNAPII CTD for productive elongation. COBRA1 is predicted to adopt a HEAT repeat fold, mediating essential intersubunit interactions that anchor NELF-A and RNA-binding NELF-E, thereby stabilizing the NELF complex and facilitating its association with paused RNAPII approximately 20–60 bp downstream of promoters. COBRA1’s principal functions include maintaining RNAPII pausing to allow rapid, signal-dependent gene induction, particularly at developmental and stress-responsive genes, modulating nuclear receptor activity (estrogen, androgen, glucocorticoid receptors) to control target gene expression and alternative splicing, and negatively regulating AP-1 at promoters such as TFF1; notably, it was initially identified through its BRCT-domain interaction with the BRCA1 tumor suppressor. COBRA1 fine-tunes transcriptional output for energy metabolism genes in cardiomyocytes, governs stem cell differentiation, and modulates hormone-driven proliferation. Clinically, reduced COBRA1 expression correlates with poor prognosis in metastatic or recurrent breast cancer, whereas its overexpression promotes androgen receptor signaling and tumor growth/migration in prostate and hepatocellular cancers.

References
https://pubmed.ncbi.nlm.nih.gov/28112367/ https://pubmed.ncbi.nlm.nih.gov/37591184/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%